J Magn Reson Imaging. 2021 May 15. doi: 10.1002/jmri.27684. Online ahead of print.
ABSTRACT
BACKGROUND: Endometrial carcinoma (EC) risk stratification is generally based on histological assessment. It would be beneficial to perform risk stratification noninvasively by MRI.
PURPOSE: To investigate the application of amide proton transfer-weighted imaging (APTWI), monoexponential, biexponential, and stretched exponential intravoxel incoherent motion (IVIM), and diffusion kurtosis imaging (DKI) for the evaluation of risk stratification in early-stage EC.
STUDY TYPE: Prospective.
POPULATION: Eighty patients with early-stage EC (47 classified as low risk, 20 as medium risk, and 13 as high risk by histological grade and International Federation of Gynecology and Obstetrics stage).
FIELD STRENGTH/SEQUENCE: T1-weighted imaging, T2-weighted imaging, IVIM, APTWI, and DKI MRI at 3 T.
ASSESSMENT: The magnetization transfer ratio asymmetry (MTRasym [3.5 ppm]), apparent diffusion coefficient (ADC), diffusion coefficient (D), pseudo diffusion coefficient (D*), perfusion fraction (f), distributed diffusion coefficient (DDC), water molecular diffusion heterogeneity index (α), mean kurtosis (MK), and mean diffusivity (MD) were calculated and compared between low-risk and non-low-risk groups.
STATISTICAL TESTS: Individual sample t test, analysis of variance, and logistic regression. A P-value <0.05 was considered statistically significant.
RESULTS: The α, ADC, D, DDC, and MD were significantly higher and the f, MK, and MTRasym (3.5 ppm) were significantly lower in the low-risk group than in the non-low-risk group. The difference in D* between the two groups was not significant (P = 0.289). MTRasym (3.5 ppm), D, and MK were independent predictors of risk stratification. The combination of these three parameters was better able to identify low- and non-low-risk groups than each individual parameter.
DATA CONCLUSION: The IVIM, DKI, and APTWI parameters have potential as imaging markers for risk stratification in early-stage EC.
LEVEL OF EVIDENCE: 2 TECHNICAL EFFICACY: Stage 3.
PMID:33991377 | DOI:10.1002/jmri.27684
